Institutional members access full text with Ovid®

Ipilimumab-induced Autoimmune Pancytopenia in a Case of Metastatic Melanoma

du Rusquec, Pauline*; Saint-Jean, Melanie*,†; Brocard, Anabelle*,†; Peuvrel, Lucie*,†; Khammari, Amir*,†; Quéreux, Gaelle*,†; Dréno, Brigitte*,†

doi: 10.1097/CJI.0000000000000041
Clinical Study

A 77-year-old patient treated with ipilimumab (anti-CTLA-4 antibody) for metastatic melanoma developed autoimmune pancytopenia (anemia, thrombocytopenia, and neutropenia) 8 days after the fourth infusion. This pancytopenia was resistant to high-dose oral corticosteroids (1 mg/kg) and to hematopoietic growth factors. It resolved after intravenous immunoglobulins injection. To date, only 1 case of autoimmune pancytopenia has been reported after this treatment. According to the case that we report, it seems essential to control the leukocyte count before any injection of ipilimumab.

Departments of *Dermato-Oncology

CIC Biotherapy INSERM U892, Hôtel-Dieu University Hospital, Nantes, France

Reprints: Brigitte Dréno, Dermato-Oncology, 1 Place A Ricordeau, Nantes Cedex 44093, France (e-mail: brigitte.dreno@wanadoo.fr).

Received November 26, 2013

Accepted March 17, 2014

© 2014 by Lippincott Williams & Wilkins